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Beata Lukaszczyk 1, Krzysztof Âlosarek 2
I n t r o d u c t i o n. Definitive radiation therapy has been established as an effective treatment in patients with advanced
cervical cancer. The aim of the study is to evaluate the results of MDR brachytherapy and external beam radiation in patients
with cervical cancer in stages II b and III.
M a t e r i a l  a n d  m e t h o d s. Between 1981 and 1986 161 patients with advanced cervical cancer (34 – stage II b; 127 – stage
III acc. to FIGO scale) were treated in the Institute of Oncology in Gliwice. The treatment was one of combined radiotherapy:
external beam radiation (60Co photons) and original MDR brachytherapy 137Cs based on individually selected applicators
and fractionation schedule.
R e s u l t s. The 5-year disease-free survival rate for patients with stage II b tumours was 60%, with stage III – 41%. In 54
patients (33,5%) clinical examination after the completion of treatment revealed persistent disease, 26 patients (16%)
developed local recurrences, 11 patients (7%) – distant metastases. Treatment tolerance in the analysed group was good. Severe
postradiation complications were noted in 2 cases (1%).
C o n c l u s i o n. The efficiency and tolerance of cervical cancer treatment combined with MDR brachytherapy was good
and comparable with data reported in literature.
Ocena wyników brachyterapii MDR i teleradioterapii
u chorych na zaawansowanego raka szyjki macicy
W s t ´ p. Radioterapia jest podstawowà metodà leczenia chorych na zaawansowanego raka szyjki macicy i polega na
skojarzeniu napromieniania od zewnàtrz i leczenia wewnàtrzjamowego. Celem pracy jest ocena wyników brachyterapii
Êrednimi mocami dawek (MDR BT) i teleterapii (TT) u chorych na zaawansowanego raka szyjki macicy.
M a t e r i a ∏  i m e t o d a. Materia∏ stanowi∏o 161 chorych leczonych radykalnie w Centrum Onkologii-Instytucie w Gliwicach
w latach 1981-1986. U 34 chorych stwierdzono stopieƒ zaawansowania II b, a u 127 – III wed∏ug FIGO. Wszystkie chore
poddano radykalnej TT (60Co) oraz MDR BT (137Cs), opartej o indywidualny dobór aplikatorów i oryginalny schemat
frakcjonowania.
W y n i k i. Prawdopodobieƒstwo pi´cioletniego prze˝ycia bezobjawowego chorych na raka szyjki macicy w stopniu
II b wynosi∏o 60%, w stopniu III – 41%. Niewyleczenie stwierdzono u 54 chorych (33,5%), wznow´ w okresie obserwacji
u 26 chorych (16%), a przerzuty odleg∏e u 11 chorych (7%). Nie zanotowano ci´˝kich wczesnych odczynów po-
promiennych, a póêne powik∏ania (III i IV stopnia wed∏ug skali EORTC/RTOG) ze strony odbytnicy stwierdzono
u 2 chorych (1%).
Po d s u m o w a n i e. Skojarzona brachyterapia MDR i teleterapia w leczeniu chorych na zaawansowanego raka szyjki
macicy charakteryzowa∏a si´ dobrà skutecznoÊcià i tolerancjà porównywalnà z danymi literaturowymi.
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Introduction
Carcinoma of the uterine cervix is still one of the
most common malignant neoplasms in women. Definitive
radiation therapy alone, combined with teletherapy (TT)
and brachytherapy (BT) has been established as an ef-
fective form of treatment in patients with advanced cervi-
cal cancer (stage II b and III).
During the past 20 years, owing to the introduction
of remote control afterloading into clinical practice, tradi-
tional brachytherapy based on Low Dose Rate techni-
que (LDR 0.4÷2 Gy/h) has been gradually replaced with
Medium Dose Rate (MDR 2÷12 Gy/h) and High Dose
Rate technique (HDR >12 Gy/h). Those modifications
were caused mainly by such practical considerations as
shortening application time and reducing the exposure
of medical staff to ionizing radiation [1, 2]. Introduction of
MDR and HDR into clinical practice influenced the ne-
cessity of the total dose fractionation [3, 4]. The Institute
of Oncology was the first in Poland to introduce MDR
brachytherapy with 137 Cs source (Selectron MDR after-
loader by Nucletron). There are only a few studies in lite-
rature concerning MDR brachytherapy in cervical cancer
treatment.
The Institute of Oncology in Gliwice has originally
introduced the method, which is discussed here, i.e. in
advanced cervical cancer treatment. It combines TT and
MDR BT based on individually selected applicators. This
method constituted an essential breakthrough in imple-
menting of HDR BT in clinical practice in our Brachythe-
rapy Department.
The aim of the study is to evaluate MDR brachy-
therapy combined with teletherapy in advanced cervical
cancer patients treated in the Institute of Oncology in
Gliwice.
Material and methods
A retrospective analysis of 161 patients with histologically confir-
med advanced cervical cancer treated with definitive radiation
alone at the Institute of Oncology in Gliwice, Poland between
the years 1981 and 1986 has been performed. The mean age of
patients at the time of treatment was 56 years (range 26÷81
years). All patients were staged clinically according to the Inter-
national Federation of Gynecology and Obstetrician (FIGO)
system [5]. Distribution of the stages was as follows: 34 (21%) ca-
ses in II b and 127 (79%) in III (4 patients in IIIa and 123 in III
b). Histological examination revealed squamous cell carcinoma
in 149 (93%) patients, adenocarcinoma in 8 (5%) patients and
solid tumor in 4 (2%).
All patients were treated with 60Co machine with ante-
rior and posterior opposing fields to the whole pelvis. The total
dose of 40-54 Gy was administered in 20-27 daily fractions, 2 Gy
per fraction. Brachytherapy was introduced after completing
20Gy to the entire pelvis from TT and was performed twice
a week with 3-day-intervals between insertions. The TT was
continued on non-BT days with a 4-cm wide midline block to
shield critical organs. The total TT time ranged from 4 to 6 we-
eks. one hundred and forty six patients completed this sche-
dule. In 15 cases the total TT dose was below 40 Gy due to dise-
ase progression and/or poor performance status during the tre-
atment.
MDR brachytherapy with 137Cs remote afterloader was
performed according to the following rules:
– total dose divided into fractions,
– treatment twice a week,
– treatment separately in vagina (vaginal applicators) and
in uterine cavity (intrauterine applicators).
Applied dose rate ranged from 8 to 10 Gy/h. The type of
intrauterine tube depended on the uterine cavity length. Vaginal
applicators were selected individually to match each pa-
tient's anatomical conditions and the extension of the tumor in-
filtration in vagina. Seventy one patients underwent intravaginal
treatment with a 3-channel flat applicator, constructed in our
Department (the tumour involved the vaginal walls), 45 with
plate and 2 with multichannel cylinder. In case of changes in
the anatomical conditions during treatment (vaginal stenosis,
narrowing of the vaginal part of the cervix) the type of vaginal
applicator was reselected (43 cases). The irradiation schedule
(number of fractions, total dose from BT) depended on the sta-
ge of the disease and the degree of tumor regression during tre-
atment. Dose per fraction was administered in reference points
located 0.5 cm or 1 cm from the applicator surface. The prescrip-
tion for total dose from BT in vagina varied from 26 Gy (referen-
ce points 1 cm from the applicator surface) to 98 Gy (reference
points 0.5 cm from the applicator surface) applied in 3-15 frac-
tions. The total dose from BT in the uterine cavity was escalated
depending upon tumor extension in the cervical canal, metrorr-
hagia and early treatment complications. It ranged from 10 to 30
Gy applied in 1-3 fractions (reference points 1 cm from the ap-
plicator surface). In 1 patient the total dose from BT in uterine
cavity was escalated to 45 Gy due to main tumor localization in
the uterine cavity and bleeding from uterine canal. Four pa-
tients received 5 Gy in the uterine cavity and intrauterine BT was
not continued due to early treatment complications. In 9 pa-
tients anatomical conditions rendered BT in the uterine cavity
impossible.
The combined treatment effectiveness was analyzed ba-
sing on:
– 5 year disease free survival rate,
– number of persistent diseases (lack of total tumor re-
gression in clinical examination within 6 months from the end of
the treatment),
– number of local recurrences (recurrence of the disease
after 6 months from the end of the treatment).
Treatment side effects were assessed basing upon revealed
complications (type, grade, localization and time of occurrence)
according to the EORTC/RTOG scale. Patients with treatment
sequelae that occurred during treatment, or within 6 months
from its termination were considered as early complication cases;
those who revealed sequelae after 6 months from the termina-
tion of treatment – as late complication cases.
The probability of disease free survival was calculated by
the Kaplan-Meyer method.
Results
The probability of 5-year disease free survival for cervical
cancer was 0,6 for patients in stage II b and 0.41 in stage
III, while the probability of 10-year disease free survival
was 0.53 and 0.4 respectively (Fig. 1).
In the analysed group of 161 patients persistent dise-
ase was stated in 54 patients (33.5%), local recurrence
in 26 patients (16%) and distant metastases in 11 patients
(7%). The reasons of treatment failures are presented in
table I.
Early irradiation sequelae grade I° and II° were ob-
served in 22 patients (14 %) in the urinary bladder and in
22 (14 %) – in the rectum. No severe early side effects ra-
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ted as grade III° and IV° were noted. Eight patients (5%)
revealed grade I° and II° late bladder complications and 6
patients (4%) late rectal complications. No late complica-
tions rated as III° were recorded. Two patients (1%) reve-
aled severe IV° late treatment complications – recto-vagi-
nal fistula requiring surgical intervention and an artifi-
cial anus. In the first of these cases routine medical
control examination held 10 months after treatment com-
pletion revealed anterior rectal wall ulceration with smo-
oth margins. Once the fistula had been formed, surgical
intervention was performed in the 15th month. In the se-
cond – 5 years after treatment completion the patient
began to complain of strong pain in the lower abdomen
and dyschezia. Microscopic examination of the excised
rectal tissue confirmed chronic colitis. Despite intensive
pharmacological treatment, a year later a recto-vaginal fi-
stula developed and surgery (ending with an artificial
anus) had to be performed. Both patients received equal
total doses from TT (50 Gy) and from BT in vagina (30
Gy in reference point 0.5 cm from the applicator surface).
The total dose from BT in uterine cavity differed: 30 Gy
in the first case and 10 Gy in the second referred in points
located 1 cm from the applicator surface.
Discussion
Retrospective analysis of treatment results obtained for
161 patients with advanced cervical cancer treated at the
Institute of Oncology in Gliwice between the years 1981
and 1986 constitutes a base for the evaluation of definiti-
ve irradiation combined with MDR BT and TT (60Co).
Considering the fact that there are only a few literature
reports describing the results of MDR brachytherapy in
gynaecological malignancies, data related to HDR and
LDR brachytherapy results was also taken into account
[6, 7].
The probability of 5-year disease free survival in the
analyzed group of patients was 0.6 in stage II b and 0.41 in
stage III. The summarized data published in literature
in relation to the results of definitive radiotherapy in ad-
vanced cervical cancer reported 5 year disease free survi-
val probability in the range of 0.56-0.59 in patients with
stage II b and 0.37-0.47 in patients with stage III [8-12]. A
few randomized studies have been published comparing
HDR and LDR brachytherapy for carcinoma of the ce-
rvix. No significant differences in local control and su-
rvival rates between HDR and LDR group were reported
in these studies [13-15], however recently published stu-
dies indicated lower survival and pelvic control rates ob-
served for stage III b patients treated with HDR brachy-
therapy [16].
The basic cause of treatment failure in advanced ce-
rvical cancer is either persistent disease or local recur-
rence. According to data from literature no regression is
observed in some 15÷30% patients with stage II b and
36÷43% in stage III treated with HDR BT [17]. The inci-
dence of no response in the analyzed group was 23% in II
b and 44% in III. Pelvic recurrences are reported within
the range of 23% in IIb and 42% in III [18, 19], however
in our material local recurrence was recognized in 21% in
II b and 17% in III. The incidence of pelvic failure is
Fig. 1. Disease free survivals according to the FIGO staging system in
advanced cervical cancer (CCU)
Tab. I. Treatment failures in advanced cervical cancer (CCU) patients treated with definitive radiotherapy
DISEASE TREATMENT persistent local distant
STAGE FAILURES disease recurrence metastases
number of patients (%) number of patients (%) number of patients (%)
CCU II b 18 / 34 (52.9%) 8 / 34 (23.5%) 7 / 34 (20.6%) 3 / 34 (8.8%)
* * *
⇒ vagina 1 (3%) ⇒ vagina 3 (9%) ⇒ bones 1 (3%)
⇒ parametrium 3 (8.5%) ⇒ parametrium 2 (6%) ⇒ distant lymph nodes  1 (3%)
⇒ parametrium and vagina 3 (8.5%) ⇒ parametrium and vagina 1 (3%) ⇒ skin in pubic symphysis 
region 1 (3%)
⇒ parametrium, vagina and cervix 1 (3%) ⇒ parametrium and cervix 1 (3%)
CCU III 73 / 127 (57.5%) 46 / 127 (36.2%) 19 / 127 (15%) 8 / 127 (6.3%)
* * *
⇒ vagina 14 (11%) ⇒ vagina 3 (2%) ⇒ lungs 4 (2.5%)
⇒ parametrium 18 (14%) ⇒ parametrium 10 (8%) ⇒ disseminated 2 (1.5%)
⇒ parametrium and vagina 2 (1.5%) ⇒ vagina and parametrium 6 (5%) ⇒ distant lymph nodes 1 (1%)
⇒ parametrium and cervix 3 (2.5%) ⇒ bones 1 (1%)
⇒ parametrium, vagina and cervix 9 (7%)
TOTAL 91 / 161 (56.5%) 54 / 161 (33.5%) 26 / 161 (16.2%) 11 / 161 (6.8%)
* Note: percentage values in brackets are given approximately
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comparable in groups treated with HDR and LDR BT
[13, 14]. A relatively low percentage of local recurrences
together with a high percentage of treatment failures in
patients with stage III of the disease may be connected
with the period of 6 months, during which no regression is
classified as persistent disease. Distant metastases are
a rather uncommon reason of treatment failures in cervi-
cal cancer patients. The incidence of distant metastases in
literature is between 8 and 34%, while in the analysed
group – only 7% [10, 20].
The analysis of treatment toxicity, as reported in lite-
rature, is difficult due to lack of a single commonly used
radiation morbidity scoring system [21]. Early complica-
tions grade I and II were observed in 14% of the cases
both in the bladder and in the rectum. No severe early
complication was noted. Literature reports present com-
plication rates to be between 10 and 25% for stage II
b and III [10, 22, 23]. In the analysed material the inciden-
ce of late complication rate was 9% including 1% of IV
grade side effects.
Conclusion
Our results suggest, that Medium Dose Rate brachythera-
py has good efficacy and tolerance in definitive radiothe-
rapy of advanced cervical cancer.
Agata Rembielak M.D. B.Sc
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